Ginkgo Bioworks (DNA) Short Interest Ratio & Short Volume $12.42 -0.36 (-2.78%) Closing price 08/27/2025 03:59 PM EasternExtended Trading$12.73 +0.31 (+2.45%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Ginkgo Bioworks Short Interest DataGinkgo Bioworks (DNA) has a short interest of 8.25 million shares, representing 20.67% of the float (the number of shares available for trading by the public). This marks a -20.21% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 1.56 million shares to cover all short positions.Current Short Interest8,250,000 sharesPrevious Short Interest10,340,000 sharesChange Vs. Previous Month-20.21%Dollar Volume Sold Short$108.10 millionShort Interest Ratio5.7 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares59,200,000 sharesFloat Size39,910,000 sharesShort Percent of Float20.67%Today's Trading Volume1,463,731 sharesAverage Trading Volume1,562,634 sharesToday's Volume Vs. Average94% Short Selling Ginkgo Bioworks? Sign up to receive the latest short interest report for Ginkgo Bioworks and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDNA Short Interest Over TimeDNA Days to Cover Over TimeDNA Percentage of Float Shorted Over Time Ginkgo Bioworks Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20258,250,000 shares $108.10 million -20.2%20.7%5.7 $13.10 7/15/202510,340,000 shares $97.46 million -14.0%27.1%7.5 $9.43 6/30/202512,020,000 shares $135.71 million +6.3%31.5%9 $11.29 6/15/202511,310,000 shares $101.10 million -4.3%29.7%9.3 $8.94 5/31/202511,820,000 shares $82.27 million +2.9%31.6%9.6 $6.96 5/15/202511,490,000 shares $88.36 million -1.2%30.7%8 $7.69 4/30/202511,630,000 shares $85.71 million -12.8%31.1%7.1 $7.37 4/15/202513,340,000 shares $110.48 million +17.0%36.1%8 $8.28 3/31/202511,400,000 shares $65.04 million +14.2%30.8%6.9 $5.71 3/15/20259,980,000 shares $69.81 million +10.2%27.0%6 $7.00 Get the Latest News and Ratings for DNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. 2/28/20259,060,000 shares $74.25 million +3.5%24.5%5.3 $8.20 2/15/20258,750,000 shares $128.84 million +6.1%24.0%5.4 $14.73 1/31/20258,250,000 shares $110.10 million +5.4%22.6%5.5 $13.35 1/15/20257,830,000 shares $72.98 million +6.2%21.5%5.9 $9.32 12/31/20247,370,000 shares $72.37 million +2.8%20.2%5.9 $9.82 12/15/20247,170,000 shares $67.68 million -3.4%19.7%6.1 $9.44 11/30/20247,420,000 shares $64.55 million +1.4%20.4%5.7 $8.70 11/15/20247,320,000 shares $46.63 million -0.1%19.7%5.5 $6.37 10/31/20247,330,000 shares $55.93 million -7.0%20.7%5.4 $7.63 10/15/20247,880,000 shares $61.46 million -3.8%22.2%5.5 $7.80 9/30/20248,190,000 shares $66.87 million +29.0%23.1%5.5 $8.17 9/15/20246,350,000 shares $40.13 million -11.2%17.9%3.6 $6.32 8/31/20247,150,000 shares $47.83 million +86.2%20.2%4.5 $6.69 8/15/20243,840,000 shares $974.98 thousand -96.9%10.8%2.6 $0.25 7/31/2024123,460,000 shares $46.91 million +27.0%8.7%2.1 $0.38 7/15/202497,240,000 shares $28.19 million -19.7%6.9%1.6 $0.29 6/30/2024121,100,000 shares $40.48 million -49.2%8.5%2.1 $0.33 6/15/2024238,220,000 shares $107.13 million -2.9%17.0%5.1 $0.45 5/31/2024245,410,000 shares $128.57 million -10.6%17.7%6.1 $0.52 5/15/2024274,440,000 shares $232.09 million -5.3%19.7%7.2 $0.85 4/30/2024289,730,000 shares $258.18 million +8.7%20.8%9.4 $0.89 4/15/2024266,530,000 shares $253.76 million -1.6%19.7%10.8 $0.95 3/31/2024270,830,000 shares $314.16 million +3.3%20.2%12.2 $1.16 3/15/2024262,240,000 shares $283.22 million +2.6%19.6%11.9 $1.08 2/29/2024255,720,000 shares $391.25 million +2.2%19.1%11.2 $1.53 2/15/2024250,230,000 shares $387.86 million +5.6%19.0%11.8 $1.55 1/31/2024236,910,000 shares $286.66 million +1.3%18.0%11.2 $1.21 1/15/2024233,850,000 shares $304.01 million -0.7%17.7%11.1 $1.30 12/31/2023235,500,000 shares $398.00 million -1.5%17.8%12.1 $1.69 12/15/2023239,070,000 shares $382.51 million +3.7%18.1%12.1 $1.60NVIDIA's Worst Nightmare? (Ad)$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible.Click here to learn how to get the ticker symbol <<< 11/30/2023230,480,000 shares $297.32 million +3.4%17.5%12.4 $1.29 11/15/2023222,910,000 shares $345.51 million -5.5%17.2%11.4 $1.55 10/31/2023235,940,000 shares $323.24 million +2.2%18.6%11.9 $1.37 10/15/2023230,820,000 shares $383.16 million -1.2%18.2%11.6 $1.66 9/30/2023233,540,000 shares $422.71 million -0.4%18.4%10.7 $1.81 9/15/2023234,530,000 shares $452.64 million +13.2%18.5%10.8 $1.93 8/31/2023207,170,000 shares $484.78 million +0.4%16.4%9 $2.34 8/15/2023206,330,000 shares $367.27 million -3.9%16.4%8.5 $1.78 7/31/2023214,590,000 shares $538.62 million -1.4%17.2%9.1 $2.51 7/15/2023217,710,000 shares $444.13 million -2.4%17.4%9.4 $2.04 6/30/2023223,020,000 shares $414.82 million +20.6%17.8%10.3 $1.86 6/15/2023184,920,000 shares $361.52 million +0.9%14.8%8.7 $1.96 5/31/2023183,290,000 shares $289.60 million -9.4%14.7%9.1 $1.58 5/15/2023202,240,000 shares $266.96 million +7.5%16.2%10.1 $1.32 4/30/2023188,130,000 shares $229.52 million -4.4%15.3%10 $1.22 4/15/2023196,750,000 shares $255.78 million +2.1%16.7%10.2 $1.30 3/31/2023192,710,000 shares $256.30 million +11.3%19.1%9.7 $1.33 3/15/2023173,100,000 shares $230.22 million +18.4%17.1%8.3 $1.33 2/28/2023146,150,000 shares $214.84 million +16.8%14.5%6.8 $1.47 2/15/2023125,180,000 shares $227.83 million +1.4%12.4%5.9 $1.82 1/31/2023123,490,000 shares $240.81 million -1.6%12.1%5.3 $1.95 1/15/2023125,510,000 shares $233.45 million -0.6%12.4%5.3 $1.86 12/30/2022126,250,000 shares $213.36 million +10.5%12.5%5.2 $1.69 12/15/2022114,290,000 shares $186.29 million -3.6%11.0%4.5 $1.63 11/30/2022118,570,000 shares $235.95 million -4.7%12.6%4.8 $1.99 11/15/2022124,380,000 shares $332.09 million -7.3%13.2%5 $2.67 10/31/2022134,220,000 shares $366.42 million -14.1%15.7%4.9 $2.73 10/15/2022156,300,000 shares $404.82 million -8.8%19.2%5.9 $2.59 9/30/2022171,280,000 shares $534.39 million -8.7%24.2%6.8 $3.12 9/15/2022187,610,000 shares $587.22 million +4.8%22.1%7.4 $3.13 8/31/2022179,060,000 shares $481.67 million +24.1%22.8%7 $2.69 8/15/2022144,250,000 shares $503.43 million -4.0%18.4%5.5 $3.49 7/31/2022150,270,000 shares $429.77 million +3.9%19.8%6.5 $2.86 7/15/2022144,640,000 shares $433.92 million +7.5%19.1%6.2 $3.00 6/30/2022134,540,000 shares $320.21 million +22.4%17.8%5.7 $2.38 6/15/2022109,920,000 shares $284.69 million -14.7%14.6%4.3 $2.59 5/31/2022128,780,000 shares $396.64 million +19.1%17.1%5.6 $3.08 5/15/2022108,160,000 shares $287.71 million +16.9%14.4%5.2 $2.66 4/30/202292,500,000 shares $268.25 million +13.8%11.8%5 $2.90 4/15/202281,300,000 shares $312.19 million +9.7%10.3%4.6 $3.84 3/31/202274,120,000 shares $298.70 million -16.4%9.4%4.4 $4.03 3/15/202288,670,000 shares $258.03 million +2.9%9.3%7.1 $2.91 2/28/202286,190,000 shares $387.86 million +1.5%9.4%7.3 $4.50 2/15/202284,950,000 shares $471.47 million -9.2%9.2%7.5 $5.55 1/31/202293,570,000 shares $559.55 million +30.3%10.2%8.9 $5.98 1/15/202271,830,000 shares $415.90 million +30.0%8.6%8.2 $5.79 12/31/202155,270,000 shares $459.29 million No Change6.4%7 $8.31 DNA Short Interest - Frequently Asked Questions What is Ginkgo Bioworks' current short interest? Short interest is the volume of Ginkgo Bioworks shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 8,250,000 shares of DNA short. 20.67% of Ginkgo Bioworks' shares are currently sold short. Learn More on Ginkgo Bioworks' current short interest. What is a good short interest ratio for Ginkgo Bioworks? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNA shares currently have a short interest ratio of 6.0. Learn More on Ginkgo Bioworks's short interest ratio. Which institutional investors are shorting Ginkgo Bioworks? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ginkgo Bioworks: Group One Trading LLC, Bank of America Corp DE, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Ginkgo Bioworks? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.67% of Ginkgo Bioworks' floating shares are currently sold short. Is Ginkgo Bioworks' short interest increasing or decreasing? Ginkgo Bioworks saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 8,250,000 shares, a decline of 20.2% from the previous total of 10,340,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Ginkgo Bioworks' float size? Ginkgo Bioworks currently has issued a total of 59,200,000 shares. Some of Ginkgo Bioworks' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ginkgo Bioworks currently has a public float of 39,910,000 shares. How does Ginkgo Bioworks' short interest compare to its competitors? 20.67% of Ginkgo Bioworks' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ginkgo Bioworks: Twist Bioscience Corporation (17.83%), Kymera Therapeutics, Inc. (14.17%), Scholar Rock Holding Corporation (17.84%), Bausch Health Cos Inc. (2.50%), Xenon Pharmaceuticals Inc. (9.47%), AMNEAL PHARMACEUTICALS, INC. (3.42%), HUTCHMED (China) Limited Sponsored ADR (0.23%), Ultragenyx Pharmaceutical Inc. (8.39%), NewAmsterdam Pharma Company N.V. (11.51%), Crinetics Pharmaceuticals, Inc. (14.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Ginkgo Bioworks stock? Short selling DNA is an investing strategy that aims to generate trading profit from Ginkgo Bioworks as its price is falling. DNA shares are trading down $0.36 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ginkgo Bioworks? A short squeeze for Ginkgo Bioworks occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNA, which in turn drives the price of the stock up even further. How often is Ginkgo Bioworks' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNA, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Twist Bioscience Short Interest Data Kymera Therapeutics Short Interest Data Scholar Rock Short Interest Data Bausch Health Cos Short Interest Data Xenon Pharmaceuticals Short Interest Data AMNEAL PHARMACEUTICALS Short Interest Data HUTCHMED Short Interest Data Ultragenyx Pharmaceutical Short Interest Data NewAmsterdam Pharma Short Interest Data Crinetics Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:DNA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access